Valsamo K Anagnostou

Summary

Affiliation: Yale University
Country: USA

Publications

  1. ncbi High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology
    Valsamo K Anagnostou
    Department of Pathology, Yale University School of Medicine, New Haven, CT, USA
    BMC Cancer 10:186. 2010
  2. ncbi Molecular classification of nonsmall cell lung cancer using a 4-protein quantitative assay
    Valsamo K Anagnostou
    Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
    Cancer 118:1607-18. 2012
  3. ncbi Analytic variability in immunohistochemistry biomarker studies
    Valsamo K Anagnostou
    Department of Pathology, Yale Cancer Center, New Haven, CT, USA
    Cancer Epidemiol Biomarkers Prev 19:982-91. 2010
  4. ncbi Multiplexed analysis of angiogenesis and lymphangiogenesis factors predicts outcome for non-small cell lung cancer patients
    Valsamo K Anagnostou
    Third Department of Medicine, Sotiria General Hospital, Athens, Greece
    Virchows Arch 458:331-40. 2011
  5. ncbi High expression of mammalian target of rapamycin is associated with better outcome for patients with early stage lung adenocarcinoma
    Valsamo K Anagnostou
    Department of Pathology, Section of Medical Oncology, Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut 06520 8023, USA
    Clin Cancer Res 15:4157-64. 2009
  6. ncbi Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma
    Valsamo K Anagnostou
    Department of Pathology, Yale University School of Medicine, New Haven, CT 06520 8023, USA
    J Clin Oncol 27:271-8. 2009
  7. ncbi Quantitative evaluation of protein expression as a function of tissue microarray core diameter: is a large (1.5 mm) core better than a small (0.6 mm) core?
    Valsamo K Anagnostou
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06520 8023, USA
    Arch Pathol Lab Med 134:613-9. 2010
  8. ncbi Differential sensitivity to platinum-based chemotherapy in primary uterine serous papillary carcinoma cell lines with high vs low HER-2/neu expression in vitro
    Sarah N Cross
    Department of Obstetrics, Yale University School of Medicine, New Haven, CT 06520 8063, USA
    Am J Obstet Gynecol 203:162.e1-8. 2010

Detail Information

Publications8

  1. ncbi High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology
    Valsamo K Anagnostou
    Department of Pathology, Yale University School of Medicine, New Haven, CT, USA
    BMC Cancer 10:186. 2010
    ..Bcl-2 has been investigated as a prognostic factor in non small cell lung cancer (NSCLC) patients with conflicting results...
  2. ncbi Molecular classification of nonsmall cell lung cancer using a 4-protein quantitative assay
    Valsamo K Anagnostou
    Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
    Cancer 118:1607-18. 2012
    ..Here we describe the development and validation of a 4-protein classifier that differentiates primary lung adenocarcinomas (AC) from squamous cell carcinomas (SCC)...
  3. ncbi Analytic variability in immunohistochemistry biomarker studies
    Valsamo K Anagnostou
    Department of Pathology, Yale Cancer Center, New Haven, CT, USA
    Cancer Epidemiol Biomarkers Prev 19:982-91. 2010
    ..Here we describe the effect of variable antibody reagents in the assessment of cancer-related biomarkers by IHC...
  4. ncbi Multiplexed analysis of angiogenesis and lymphangiogenesis factors predicts outcome for non-small cell lung cancer patients
    Valsamo K Anagnostou
    Third Department of Medicine, Sotiria General Hospital, Athens, Greece
    Virchows Arch 458:331-40. 2011
    ..Angiogenic and lymphangiogenic biomarkers studied define subgroups of patients at high risk and may be useful for prognostic stratification of NSCLC patients especially those with early stage disease...
  5. ncbi High expression of mammalian target of rapamycin is associated with better outcome for patients with early stage lung adenocarcinoma
    Valsamo K Anagnostou
    Department of Pathology, Section of Medical Oncology, Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut 06520 8023, USA
    Clin Cancer Res 15:4157-64. 2009
    ..Here, we quantitatively assessed mTOR protein expression in two large data sets to investigate the impact of mTOR expression on patient survival...
  6. ncbi Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma
    Valsamo K Anagnostou
    Department of Pathology, Yale University School of Medicine, New Haven, CT 06520 8023, USA
    J Clin Oncol 27:271-8. 2009
    ..We quantitatively assessed TTF1 protein expression in two large and independent data sets to investigate the impact of TTF1 nuclear expression on patient survival...
  7. ncbi Quantitative evaluation of protein expression as a function of tissue microarray core diameter: is a large (1.5 mm) core better than a small (0.6 mm) core?
    Valsamo K Anagnostou
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06520 8023, USA
    Arch Pathol Lab Med 134:613-9. 2010
    ..6-mm to 1.5-mm core "biopsies" of standard formalin-fixed, paraffin-embedded tissue blocks and by the processing of hundreds of cases arrayed on a single recipient block in an identical manner...
  8. ncbi Differential sensitivity to platinum-based chemotherapy in primary uterine serous papillary carcinoma cell lines with high vs low HER-2/neu expression in vitro
    Sarah N Cross
    Department of Obstetrics, Yale University School of Medicine, New Haven, CT 06520 8063, USA
    Am J Obstet Gynecol 203:162.e1-8. 2010
    ..We sought to identify effective chemotherapy regimens against uterine serous papillary adenocarcinoma (USPC)...